Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the
Japan Generic Drugs Market
Request Now !
Generic drugs are pharmaceutical drugs with similar chemical makeup of a branded drug. Generic drugs are cheaper in Japan and equivalent to branded drugs in dosage, strength, route of administration, quality, performance, and application. Generic drugs are subjected to government regulations of Japan; the Japanese Government has observed the growth of the generic drug market as imperative to Japans long-term economic health.
The major factors that contribute to the growth of the Japan generic drugs market include increasing prevalence of chronic diseases, diabetes & cardiovascular diseases, rising costs of branded medicines, growth in geriatric population, increasing healthcare expenditure, and high demand for generic medicines. However, issues such as the consistency and stability of generic drugs in Japan and lower reimbursement fees are expected to restrain the market development. Development of reliable & stable new product launch, support from the government, and adoption of mergers & acquisition strategies to launch new products by key vendors contribute to significant demand for generic drugs in the near future.
The Japan generic drugs market is segmented on the basis of product type, application, and distribution channel. On the basis of product type, the market is segmented into generic prescription medicines, super generics, and biosimilars. Based on application the market is divided into cardiovascular products, anti-infective drugs, anti-arthritis drugs, central nervous system drugs, anti-cancer drugs, respiratory products, and others. On the basis of distribution channel, the market is segmented into hospitals, pharmacies, private clinics, drug stores, retail pharmacies, and others.
The key players that operate in this market include Teva Pharmaceutical Industries Ltd., Nichi-Iko Pharmaceutical Co., Ltd., Sawai Pharmaceuticals Co., Ltd., NIPRO Medical Corporation, Meiji Seika Pharma Co., Ltd., Towa Pharmaceutical Co., Ltd., Hikari Pharmaceutical Co., Ltd., Fuji Pharma Co., Ltd., Mylan N.V., and GlaxoSmithKline Plc.
- The study provides an in-depth analysis of the Japan generic drugs market with current trends and future estimations to elucidate imminent investment pockets.
- The report provides information about the current and upcoming trends in the Japan generic drugs market from 2016 to 2023, which helps determine prevailing opportunities.
- Comprehensive analysis of factors that drive and restrict the growth of the Japan generic drugs market has been provided.
- Identification of factors that are instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market have been provided.
- Key market players within the market have been profiled in this report and their strategies are analyzed thoroughly, which help understand the competitive outlook of the Japan generic drugs market.
Japan Generic Drugs Market Key Segments:
By Product Type
- Generic Prescription Medicines
- Super Generics
- Cardiovascular Products
- Anti-Infective Drugs
- Anti-Arthritis Drugs
- Central Nervous System Drugs
- Anti-Cancer Drug
- Respiratory Products
By Distribution Channel
- Private Clinics
- Drug Stores
- Retail Pharmacies
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.4.1. MARKET DYNAMICS
CHAPTER 4 JAPAN GENERIC DRUGS MARKET, BY PRODUCT TYPE
4.1.1. Market size and forecast
4.2. SIMPLE GENERICS
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. SUPER GENERICS
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
CHAPTER 5 JAPAN GENERIC DRUGS MARKET, BY APPLICATION
5.1.1. Market size and forecast
5.2. CARDIOVASCULAR DRUGS
5.2.1. Market size and forecast
5.3. ANTI-INFECTIVE DRUGS
5.3.1. Market size and forecast
5.4. ANTI-ARTHRITIS DRUGS
5.4.1. Market size and forecast
5.5. CENTRAL NERVOUS SYSTEM DRUGS
5.5.1. Market size and forecast
5.6. ANTI-CANCER DRUGS
5.6.1. Market size and forecast
5.7. RESPIRATORY DRUGS
5.7.1. Market size and forecast
5.8.1. Market size and forecast
CHAPTER 6 JAPAN GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1.1. Market size and forecast
6.2.1. Market size and forecast
6.3.1. Market size and forecast
6.4. PRIVATE CLINICS
6.4.1. Market size and forecast
6.5. DRUG STORES
6.5.1. Market size and forecast
6.6. RETAIL PHARMACIES
6.6.1. Market size and forecast
6.7.1. Market size and forecast
CHAPTER 7 COMPANY PROFILES
7.1. NICHI-IKO PHARMACEUTICAL CO., LTD.
7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments
7.2. TEVA PHARMACEUTICAL INDUSTRIES LTD.
7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments
7.3. SAWAI PHARMACEUTICALS CO., LTD.
7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments
7.4. NIPRO MEDICAL CORPORATION
7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments
7.5. MEIJI SEIKA PHARMA CO., LTD.
7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments
7.6. TOWA PHARMACEUTICAL CO., LTD.
7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments
7.7. HIKARI PHARMACEUTICAL CO., LTD.
7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments
7.8. FUJI PHARMA CO., LTD.
7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments
7.9. GLAXOSMITHKLINE PLC
7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments
7.10. MYLAN N.V.
7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments
With collective industry experience of about 200 years of its analysts and experts, Allied
Market Research (AMR)
encompasses most infallible research methodology for its market intelligence and industry
analysis. We do not only
engrave the deepest levels of markets but also sneak through its slimmest details for the
purpose of our market estimates
and forecasts. Our approach helps in building greater market consensus view for size, shape and
industry trends within
each industry segment. We carefully factor in industry trends and real developments for
identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data,
expert views and analysis
and high value independent opinions. Our research process is designed to deliver balanced view
of the global markets and
allow stakeholders to make informed decisions.
We offer our clients exhaustive research and analysis based on wide variety of factual inputs,
which largely include interviews with industry participants, reliable statistics and regional
intelligence. Our in-house industry experts play instrumental role in designing analytic tools
and models, tailored to the requirements of particular industry segment. These analytical tools
and models sanitize the data & statistics and enhance the accuracy of our recommendations
and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology,
our clients are assured of receiving:
- Consistent, valuable, robust and actionable data & analysis that can easily be
referenced for strategic business planning
- Technologically sophisticated and reliable insights through well audited and veracious
- Sovereign research proceeds that present a tangible depiction of marketplace
With a strong methodology we are, therefore, confident that our research and analysis are most
reliable and guarantees sound business planning.
We refer a broad array of industry sources for our secondary, which typically include; however,
not limited to:
Company SEC filings, annual reports, company websites, broker & financial reports and
investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, web-casts and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators and relevant press
releases for market estimates and forecast
Our primary research efforts include reaching out participants through mail, tele-conversations,
referrals, professional networks and face-to-face interactions. We are also in professional
corporate relations with various companies that allow us greater flexibility for reaching out
industry participants and commentators for interviews and discussions, fulfilling following
- Validates and improves the data quality and strengthens research proceeds
- Further develops analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth and forecasts
Our primary research interview and discussion panels are typically composed of most experienced
industry members. These participants include; however, not limited to:
Analyst tools and models
- Chief executives and VPs of leading corporations specific to industry
- Product and sales managers or country heads; channel partners and top level
distributors; banking, investments and valuation experts Key opinion leaders (KOLs)
AMR has developed set of analyst tools and data models to supplement and expedite the analysis
process. Corresponding to markets, where there is significant lack of information and estimates,
AMR’s team of experts and analyst develop specific analyst tools and industry models to
translate qualitative and quantitative industry indicators into exact industry estimates. These
models also allow analysts to examine the prospects and opportunities prevailing in the market
to accurately forecast the course of the market.